Overview of the Recent Developments in Chronic Lymphocytic Leukemia, Part 1

JHOP - June 2016 Vol 6, No 2 - Review Article
Download PDF
Austin J. Combest, PharmD, BCOP, MBA
Senior Director of Clinical Science
Pharmaceutical Product Development (PPD)
Department of Global Product Development
Wilmington, NC
Director
University of North Carolina/PPD Drug Development Fellowship
Chapel Hill, NC
Ryan C. Danford, PharmD
Staff Pharmacist
CVS
Burlington, NC
Elizabeth R. Andrews, PharmD
Drug Development Fellow
Pharmaceutical Product Development
Department of Global Product Development
Wilmington, NC
Ashley Simmons, PharmD
Associate Director of Clinical Operations
Parion Sciences
Raleigh-Durham, NC
Paulina McAtee, PharmD
Associate Director
Clinical Pharmacy Services
Pharmaceutical Product Development
Department of Global Product Development
Wilmington, NC
Dirk J. Reitsma, MD
Vice President and Head of Oncology
Pharmaceutical Product Development
Department of Global Product Development
Wilmington, NC

Background: The clinical development landscape for chronic lymphocytic leukemia (CLL) is evolving rapidly, and continuously challenges current therapeutic guidelines. Several new agents have recently gained approval from the US Food and Drug Administration and European Medicines Agency, including venetoclax, ibrutinib, idelalisib, and obinutuzumab. These new therapies, together with recent updates to the guidelines from the National Comprehensive Cancer Network and European Society for Medical Oncology, reflect findings of improved progression-free and overall survival rates, and represent a new age in the treatment of CLL.

Objective: The objective of this manuscript is to provide an overview of recent changes to the CLL landscape, as well as future directions to inform practitioners and clinical researchers.

Discussion: Because of these changes, it is likely that the future will bring further development of niche drugs that target cytogenetic abnormalities—specifically 11q and 17p—as well as more active and tolerable regimens for older patients. Tolerable regimens and convenient routes of administration are needed to enable outpatients to self-administer their treatment long-term, and improve their quality of life.

Conclusion: The increasing number of novel agents for CLL management present new challenges for appropriate sequencing of these agents, and comparator arm choices for future trials. Collaboration between developers can lead to more efficient and less costly clinical trials. Increased enrollment in clinical trials, especially among older patients, will be critical for the continued development of novel agents in the treatment of CLL.

J Hematol Oncol Pharm.
2016;6(2):54-56

www.JHOPonline.com

Disclosures are at end of text

From 2005 to 2014, the number of ongoing trials of chronic lymphocytic leukemia (CLL) has increased at a compound annual growth rate of 18.4%.1 This rapid growth in the CLL clinical trial landscape has led to multiple breakthroughs in the management of CLL, which have changed—and will continue to change—the treatment paradigm in the near future. One major breakthrough includes the discovery and development of agents targeting the B cell. CLL pathogenesis is a complex process that results in replication of malignant B lymphocytes. B-cell receptor signaling plays a role in B-cell survival and proliferation in CLL through the actions of protein kinases. The cells of CLL reportedly have high levels of B-cell receptor signaling activity.2 Bruton tyrosine kinase (Btk) and phosphoinositide 3-kinase delta play important roles in this signaling process once the B-cell receptor is ligated. Once Btk is activated by the Src family kinases (Blk, Lyn, and Fyn), it activates phospholipase-Cγ through phosphorylation, which mobilizes internal calcium and activates the NF-κB and mitogen-activated protein kinase pathways. People with mutations in Btk have low levels of B cells and immunoglobulins. Inhibiting these kinases has demonstrated practice-changing efficacy in CLL.3 With a better understanding of B-cell receptor signaling pathways, treatment and research focus has shifted from alkylating agents and purine analogs to alternate approaches, including targeting tyrosine kinase inhibitors and novel anti-CD20 monoclonal antibodies, which interfere with B-cell signaling. This transition has revolutionized CLL to a disease that is manageable, allowing some patients with the condition to live a normal life­span. Ongoing trials are designed to demonstrate the optimal combinations and sequences of treatments, with the possibility of developing a curative regimen for select patients.

Several novel agents have recently received breakthrough therapy designation and subsequent approval from the US Food and Drug Administration (FDA). By the end of 2014, 17 medications designated as breakthrough therapies had gained FDA approval; 11 were approvals in hematology and oncology, with 4 indicated for patients with CLL. The latter include ibrutinib (Imbruvica; Pharmacyclics LLC, Sunnyvale, CA), idelalisib (Zydelig; Gilead Sciences, Inc, Foster City, CA), ofatumumab (Arzerra; Novartis Pharmaceuticals Corporation, East Hanover, NJ), and obinutuzumab (Gazyva; Genentech, Inc, South San Francisco, CA).4 Ibrutinib received FDA approval in February 2014 for the treatment of patients with CLL who have received ≥1 previous therapies; in July 2014, accelerated approval was granted for a new indication: patients with CLL with 17p deletion/mutation (del17p). In March 2016, an additional expanded approval was granted to ibrutinib for the first-line treatment of CLL.5 At the same time, idelalisib received FDA approval for the treatment of relapsed CLL in combination with rituximab. In April 2014, the anti-CD20 monoclonal antibody ofatumumab was granted FDA approval to expand its use to patients with untreated CLL for whom fludarabine-based therapy is inappropriate. The CD20-directed cytolytic antibody, obinutuzu­mab, gained approval in November 2013 for frontline treatment of patients with CLL in combination with chlorambucil. All 4 agents also received approval from the European Medicines Agency 2 to 3 months after the FDA approval. In addition, in April 2016, the FDA granted accelerated approval of venetoclax, a Bcl-2 inhibitor, for patients with CLL with del17p, and who have been treated with ≥1 prior therapies.6

Although these breakthrough therapies have dramatically improved outcomes, their cost to patients and society is not insignificant. Ibrutinib and idelalisib are oral medications that require continuous and indefinite daily use. The average wholesale price for a 12-month supply of these agents is approximately $118,000.7 Because CLL is considered a disease of older adults, oral medications are covered by Medicare Part D in the United States. However, there are coverage gaps requiring significant out-of-pocket expenses, estimated to be $20,847 for a 30-month course of ibrutinib, and $14,449 for a 20-month course of idelalisib in the relapsed setting. The average wholesale price of obinutuzumab plus chlorambucil is $52,877 for 6 cycles of therapy; however, because obinutuzumab is an intravenous medication, it is covered by Medicare Part B in the United States, which does not have the same coverage gap as Part D. The estimated out-of-pocket expense for obinutuzumab and chlorambucil is $1179. Ofatumumab’s average wholesale price is $124,332 for 6 cycles of therapy; however, because it is an intravenous medication, the out-of-pocket costs for patients with Medicare Part B are not significant. In the future, it is expected that idelalisib and ibrutinib will gain broad approval as first-line treatment of CLL, which will lead to an even greater cost burden for the patient. Out-of-pocket costs in Europe vary, with some medications undergoing pharmacoeconomic evaluation before becoming available (as is done by the National Institute for Health and Care Excellence in the United Kingdom).

This increase in approvals has created a dynamic clinical development landscape for CLL, including increasing competition of promising agents, a change in the standard of care, and more challenging regulatory hurdles. Sequencing, and the ideal combinations of novel-novel or novel-approved regimens, are considerations for future clinical trials. These new therapies have demonstrated better progression-free and overall survival rates than those of traditional chemotherapy regimens. Although these improvements bring hope to patients and practitioners, they also create challenges for future CLL drug development. The competition has increased the threshold for expected CLL efficacy and approval for future agents, because they will be compared with these newer agents. Thus, future studies are warranted to explore biomarkers or other surrogate end points, such as minimal residual disease status, which may further guide treatment and differentiate marketed products. Cytogenetics may also play an important role in future trials and their ability to identify the best drug for each patient. To address these challenges, collaborative efforts among pharmaceutical companies may be a novel and necessary direction of future CLL research.

Part 1 of this review was undertaken to provide better understanding of the future of CLL research. Our objective for the remainder of the series is to characterize CLL and its current treatments, compare newly approved drugs to traditional regimens, identify promising medications in development, and explore potential implications for CLL drug development.

Global Epidemiology of Chronic Lymphocytic Leukemia

CLL is the most common leukemia in Western countries, representing approximately 22% to 30% of all leukemias worldwide.8,9 In certain Asian countries (eg, China, India, and Japan), the percentage of CLL cases is much lower (4%-10% of leukemias).10-14 However, these countries have large populations, so the actual number of afflicted patients might be similar. The global annual incidence is between <1 and 5.5 per 100,000 people, and more men than women are affected.10 The incidence of CLL is approximately 4.2 cases per 100,000 people in the Western world.9,15 The global CLL incidence and 3-year prevalence are shown in the Figure.16 This figure also shows that few countries have a large population with CLL, which brings to light potential challenges that arise when selecting countries and sites for studying CLL, especially in phase 3 trials. In addition to the low incidence/prevalence, there is intense competition for these patients.

Figure

Author Disclosure Statement
Dr Combest, Dr McAtee, and Dr Reitsma are employees of Pharmaceutical Product Development (PPD), Wilmington, NC. Dr Danford is a Research Fellow at PPD, and the University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC. Dr Andrews and Dr Simmons have no relevant disclosures to report.

References
1. Citeline: TrialTrove. https://ppd.citeline.com/default.asp. Accessed January 2015.
2. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175-1184.
3. O’Brien SM. Therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2010:273-278.
4. US Food and Drug Administration. Breakthrough therapy approvals. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373418.htm. Accessed May 16, 2016.
5. US Food and Drug Administration. All approvals March 2016. www.access data.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.Monthly ApprovalsAll. Accessed May 11, 2016.
6. US Food and Drug Administration. FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm. Updated April 11, 2016. Accessed May 11, 2106.
7. Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11:252-258.
8. Siegel R, Naishadham D, Ahmedin J. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
9. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. http://seer.cancer.gov/data/. Published April 2015. Accessed May 2, 2016.
10. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13:279-287.
11. Gogia A, Sharma A, Raina V, et al. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma. 2012;53:1961-1965.
12. Zheng W, Linet MS, Shu XO, et al. Prior medical conditions and the risk of adult leukemia in Shanghai, People’s Republic of China. Cancer Causes Control. 1993;4:361-368.
13. Kobayashi T, Kita K, Ohno T, Shirakawa S. Chronic lymphocytic leukemia in Japan. Rinsho Ketsueki. 1990;31:554-563.
14. Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995;75(1 Suppl):381-394.
15. Eichhorst B, Hallek M, Dreyling M. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2010;21(Suppl 5):v162-v164.
16. Leukaemia—estimated incidence and prevalence, adult population: both sexes. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/summary_table_site_prev.asp?selection=12280&title=Leukaemia&sex=0&africa=1&america=2&asia=3 &europe=4&oceania=5&build=6&window=1&sort=0&submit=%C2%A0Execute%C2%A0. Published 2012. Accessed May 16, 2016.

Related Items
Current Treatment Options for Metastatic Renal-Cell Carcinoma: Review of the Literature
Daphne O. Davis, PharmD, BCOP, Megan Hinkley, PharmD, BCOP
JHOP - December 2017 Vol 7, No 4 published on December 8, 2017 in Review Article
Enzalutamide in the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer
Adegoke O. Adeniji, BPharm, PhD, David A. Kaland, PharmD, BCOP, Launa M.J. Lynch, PhD, Vicky M. Mody, PhD
JHOP - September 2017 Vol 7, No 3 published on June 25, 2017 in Online First, Review Article
Novel Systemic Therapies for Advanced Non–Small-Cell Lung Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, Tristan Lindfelt, PharmD, BCPS, BCACP, BCOP, Eric Lozano
JHOP - March 2017 Vol 7, No 1 published on March 13, 2017 in Review Article
Overview of the Current Development Landscape in Chronic Lymphocytic Leukemia, Part 3
Austin J. Combest, PharmD, BCOP, MBA, Ryan C. Danford, PharmD, Elizabeth R. Andrews, PharmD, Ashley Simmons, PharmD, Paulina McAtee, PharmD, Dirk J. Reitsma, MD
JHOP - December 2016 Vol 6, No 4 published on December 2, 2016 in Review Article
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
Marjorie Adams Curry, PharmD, BCOP, Susanne Liewer, PharmD, BCOP
JHOP - December 2016 Vol 6, No 4 published on December 2, 2016 in Review Article
Overview of the Current Treatment Paradigm in Chronic Lymphocytic Leukemia, Part 2
Austin J. Combest, PharmD, BCOP, MBA, Ryan C. Danford, PharmD, Elizabeth R. Andrews, PharmD, Ashley Simmons, PharmD, Paulina McAtee, PharmD, Dirk J. Reitsma, MD
JHOP - Sept 2016 Vol 6, No 3 published on August 22, 2016 in Review Article
Cyanocobalamin/Salcaprozate Sodium: A Novel Way to Treat Vitamin B12 Deficiency and Anemia
Lillian Smith , PharmD, MBA, CPh, Juan Mosley, PharmD, CPh, AAHIVP, Megan Ford, PharmDc, Jonathan Courtney, PharmDc
JHOP - June 2016 Vol 6, No 2 published on June 13, 2016 in Review Article
Pembrolizumab for Recurrent Metastatic Melanoma: Review of Current Use and Future Implications
Allison A. Baxley, Dana B. Johnson, Ashley N. Huddleston
JHOP - December 2015 Vol 5, No 4 published on November 28, 2015 in Original Research, Review Article
Last modified: July 26, 2016